John S Muchmore, MD | |
5401 N Portland Ave Ste 410, Oklahoma City, OK 73112-2131 | |
(405) 945-4700 | |
(405) 945-4270 |
Full Name | John S Muchmore |
---|---|
Gender | Male |
Speciality | Endocrinology |
Experience | 49 Years |
Location | 5401 N Portland Ave Ste 410, Oklahoma City, Oklahoma |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033163100 | NPI | - | NPPES |
100116630B | Medicaid | OK |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 10850 (Oklahoma) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Integris Ambulatory Care Corporation | 2365408465 | 382 |
News Archive
Diarrheal diseases are a leading cause of death for young children, accounting for nine percent of all deaths worldwide in children under five years of age, with most occurring in children under two years of age.
RA is the commonest autoimmune arthritis affecting 1% of the general population. Despite its main articular manifestations, RA caninvolveextra-articular organs including the auditory system.
Concussion, a form of traumatic brain injury, is a common injury among children and teens. Concussions can have adverse effects on physical, cognitive, emotional and sleep health.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
BASF SE has reached an agreement with Cognis Holding Luxembourg S.a r.l. controlled by Permira Funds, GS Capital Partners and SV Life Sciences to acquire the specialty chemicals company Cognis for an equity purchase price of euro 700 million. Including net financial debt and pension obligations, the enterprise value of the transaction is euro 3.1 billion. The acquisition is subject to clearance by the competent merger control authorities. Closing of the transaction is expected for November 2010 at the latest.
› Verified 8 days ago
Entity Name | Integris Ambulatory Care Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1750333936 PECOS PAC ID: 2365408465 Enrollment ID: O20041209000354 |
News Archive
Diarrheal diseases are a leading cause of death for young children, accounting for nine percent of all deaths worldwide in children under five years of age, with most occurring in children under two years of age.
RA is the commonest autoimmune arthritis affecting 1% of the general population. Despite its main articular manifestations, RA caninvolveextra-articular organs including the auditory system.
Concussion, a form of traumatic brain injury, is a common injury among children and teens. Concussions can have adverse effects on physical, cognitive, emotional and sleep health.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
BASF SE has reached an agreement with Cognis Holding Luxembourg S.a r.l. controlled by Permira Funds, GS Capital Partners and SV Life Sciences to acquire the specialty chemicals company Cognis for an equity purchase price of euro 700 million. Including net financial debt and pension obligations, the enterprise value of the transaction is euro 3.1 billion. The acquisition is subject to clearance by the competent merger control authorities. Closing of the transaction is expected for November 2010 at the latest.
› Verified 8 days ago
Entity Name | Integris Cardiovascular Physicians Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1306129598 PECOS PAC ID: 3577730068 Enrollment ID: O20120207000415 |
News Archive
Diarrheal diseases are a leading cause of death for young children, accounting for nine percent of all deaths worldwide in children under five years of age, with most occurring in children under two years of age.
RA is the commonest autoimmune arthritis affecting 1% of the general population. Despite its main articular manifestations, RA caninvolveextra-articular organs including the auditory system.
Concussion, a form of traumatic brain injury, is a common injury among children and teens. Concussions can have adverse effects on physical, cognitive, emotional and sleep health.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
BASF SE has reached an agreement with Cognis Holding Luxembourg S.a r.l. controlled by Permira Funds, GS Capital Partners and SV Life Sciences to acquire the specialty chemicals company Cognis for an equity purchase price of euro 700 million. Including net financial debt and pension obligations, the enterprise value of the transaction is euro 3.1 billion. The acquisition is subject to clearance by the competent merger control authorities. Closing of the transaction is expected for November 2010 at the latest.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
John S Muchmore, MD 5300 N Independence Ave, Suite 280, Oklahoma City, OK 73112-5556 Ph: (405) 945-4700 | John S Muchmore, MD 5401 N Portland Ave Ste 410, Oklahoma City, OK 73112-2131 Ph: (405) 945-4700 |
News Archive
Diarrheal diseases are a leading cause of death for young children, accounting for nine percent of all deaths worldwide in children under five years of age, with most occurring in children under two years of age.
RA is the commonest autoimmune arthritis affecting 1% of the general population. Despite its main articular manifestations, RA caninvolveextra-articular organs including the auditory system.
Concussion, a form of traumatic brain injury, is a common injury among children and teens. Concussions can have adverse effects on physical, cognitive, emotional and sleep health.
Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.
BASF SE has reached an agreement with Cognis Holding Luxembourg S.a r.l. controlled by Permira Funds, GS Capital Partners and SV Life Sciences to acquire the specialty chemicals company Cognis for an equity purchase price of euro 700 million. Including net financial debt and pension obligations, the enterprise value of the transaction is euro 3.1 billion. The acquisition is subject to clearance by the competent merger control authorities. Closing of the transaction is expected for November 2010 at the latest.
› Verified 8 days ago
Evelyn Lorents, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 920 Sl Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Patrick Bronson Reeves, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3366 Nw Expressway Ste 550, Oklahoma City, OK 73112 Phone: 405-942-5442 Fax: 405-942-6448 | |
Dr. Jake Lee Evans, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Aat 6300, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Metri Haddaden, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young Blvd # 8425, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 410-554-2184 | |
Divya Sharma Divyadarshini, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Dr. Philip Barton Miner, Jr., M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1000 N Lincoln Blvd, Suite 210, Oklahoma City, OK 73104 Phone: 405-271-4644 Fax: 405-271-3296 | |
Gary Lee Worcester, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St, Ste 400, Oklahoma City, OK 73112 Phone: 405-947-3341 |